AXXZIA INC

1. Company Overview

AXXZIA INC. is a Japanese cosmetics company listed on the Tokyo Stock Exchange Standard market. It sells skincare, beauty-device, and “inner-care” products, principally through Chinese e-commerce channels, with smaller Japanese, inbound-tourist, and Southeast Asian operations. Its important brands include AXXZIA, AGTHEORY, Venus Recipe, and LisBlanc. The business has one reportable segment: cosmetics.

Data freshness matters here. The latest clean official annual base is FY2025, ended July 31, 2025, filed October 23, 2025. More recent data is partial and unaudited: the latest official update is the nine months to April 30, 2026, disclosed June 12, 2026, along with revised management guidance for FY2026. As of the supplied market date of July 30, 2026, FY2026 had not yet ended and no audited FY2026 annual report was available.

At ¥319 per share on July 30, 2026, supplied current market data implies a market capitalization of ¥7.30 billion. Net cash/debt is not determinable from the supplied deterministic valuation block and should not be treated as zero. The FY2025 audited report showed ¥3.57 billion of cash and disclosed loan balances, but the supplied data explicitly lacks the securities inputs needed for a reliable net-cash calculation; the later interim update does not provide a complete current cash-and-debt bridge.

FY2025 audited revenue was ¥13.48 billion, operating income was ¥513 million, and net income was ¥321 million. These are historical audited facts, not current earnings. The supplied FY2025 owner-earnings estimate is ¥607 million, but that is a model estimate, not an audited accounting measure. It is especially important not to capitalize it uncritically when FY2026 management guidance calls for an operating loss.

2. How the Company Makes Money

AXXZIA earns gross profit by designing and branding beauty products, outsourcing or otherwise procuring production, and selling through digital platforms, distributors, retail channels, and its own stores. China e-commerce has been the economic engine because it combines access to a large beauty market with products that historically carried higher gross margins than the acquired/imported-cosmetics activities. In the FY2026 first half, China represented ¥4.9 billion of sales, or 72.7% of reported revenue, according to the company’s unaudited management update.

The profit engine is therefore not manufacturing scale. It is brand demand translated into repeat purchases through Chinese platforms, live-streaming, key opinion leaders, advertising, and platform distribution. The same mechanism is fragile: the company must continually pay for traffic and conversion. If customer acquisition costs, influencer commissions, or platform fees rise faster than gross profit, reported sales can grow while owner earnings shrink.

Japan is being developed through LisBlanc, retail distribution, social-media marketing, and directly operated stores. The M&D subsidiary is being shifted from importing third-party cosmetics to selling its own BELLE BAI brand. Southeast Asia is being developed through influencer-led live commerce and pop-up channels. These initiatives may reduce China concentration over time, but they are still investments rather than proven profit pools.

The physical capital burden is moderate. FY2025 audited capital expenditure was ¥326 million, or roughly 2.4% of revenue, while inventories were ¥1.95 billion. The more important capital requirement is working capital, advertising, commissions, brand development, and inventory risk. This is a potentially attractive asset-light consumer business when marketing is efficient, but it is not yet demonstrably a durable high-return compounder. The sharp erosion in operating margin shows that the returns on incremental commercial spending are currently uncertain.

3. Why the Stock Fell

The dominant market narrative is a loss of confidence in the earnings power of a China-dependent beauty brand. The concern is not simply that revenue slowed; it is that the company’s paid-acquisition model has become much less profitable.

• FY2024 to FY2025 deterioration: audited revenue rose from ¥12.19 billion to ¥13.48 billion, but operating income fell from ¥918 million to ¥513 million and net income fell from ¥794 million to ¥321 million. Revenue growth did not translate into profit growth.
• March 13, 2026 interim results: first-half FY2026 revenue increased 7.8% year on year to ¥6.77 billion, but operating profit turned into a ¥15 million loss from a ¥117 million profit. Management cited heavier China advertising, Japan investment, and higher payment fees.
• June 12, 2026 nine-month results and guidance cut: nine-month revenue was ¥9.89 billion, down 1.9% year on year; operating income was a ¥49 million loss versus a ¥426 million profit in the prior-year period. Management cut FY2026 revenue guidance from ¥14.44 billion to ¥13.50 billion and cut operating-income guidance from a ¥570 million profit to a ¥250 million loss. Net-income guidance moved from a ¥370 million profit to a ¥105 million loss.

The company attributed the June revision to slower growth in China e-commerce after the second quarter, weaker Chinese inbound demand in Japan following Japan-China tensions from November 2025, weak M&D sales following price changes, and substantially higher advertising and commission costs amid more intense Chinese competition. These are observed company disclosures. The inference is that investors are discounting not merely a bad quarter, but the possibility that the former China e-commerce margin structure will not return.

No verified historical share-price peak or decline percentage was supplied, so the magnitude of the stock-price fall should not be stated as a fact. What is verified is that the current ¥7.30 billion market capitalization is below FY2025 book value and is being assigned to a business management expects to report a FY2026 operating loss.

4. What the Market Is Assuming

The market is simultaneously recognizing balance-sheet support and discounting the reliability of operating earnings. At ¥319, the supplied FY2025-based owner-earnings yield is 8.31%, while the supplied price-to-book ratio is 0.96 times. That combination implies investors are not pricing the company as an imminent insolvency, but are skeptical that historical earnings can be restored without continued high marketing expenditure.

The critical distinction is between a temporary sales disruption and a permanently lower marketing return on capital. China-related travel restrictions and weak consumption can normalize. A lasting requirement to spend more of each revenue yen on traffic and commissions cannot be normalized away; it changes the business’s sustainable margin.

5. Temporary or Structural?

Time-as-a-moat test: a well-funded competitor can recreate products, acquire influencers, buy platform traffic, and copy live-commerce tactics within two years. It may take five years to build a credible cross-border brand, repeat-purchase data, regulatory registrations, and distribution relationships. Over ten years, however, the company’s position is defensible only if its products develop genuine consumer loyalty and its direct customer relationships reduce dependence on rented platform traffic. The available evidence supports some brand recognition and regulatory progress, but not a moat strong enough to protect margins against better-funded local competitors.

The diagnosis is therefore structural but survivable, rather than a clean cyclical downturn. The business is financially resilient enough to attempt a repair, but the repair requires proof that China revenue can grow without consuming most of the gross profit in advertising and commissions. Management’s FY2026 loss guidance shows that this proof has not yet arrived.

6. Is the Market Wrong? By How Much?

Moat-and-mispricing score: 3/10. The score is low because the balance sheet and the supplied NCAV estimate provide some downside support, but the current market value already requires a substantial recovery from FY2026’s guided loss. The stock is not obviously pricing a permanent collapse; it is closer to pricing a recovery in FY2025-level owner earnings. The evidence does not yet justify assuming that recovery.

The valuation below is a FY2025-owner-earnings framework adjusted for the unaudited nine-month FY2026 deterioration and the revised FY2026 loss guidance. It is not a price target. It assumes no valuation-multiple expansion and no unverified net-cash adjustment. Stock-based compensation has not been independently verified in the supplied inputs; no stock-compensation addback is made.

Per-share values use 22.87 million shares, calculated from the supplied July 2026 market capitalization and ¥319 share price; this is consistent with the latest disclosed treasury-share-excluded count but is not presented as a new official share-count filing. Net cash/debt adjustment: none. Owner earnings are capitalized directly to equity value, and the supplied net-cash figure is unavailable. Treating unverified cash as additional value would overstate precision.

The bear case is asset-led, not earnings-led: the supplied NCAV estimate of ¥5.55 billion is useful evidence of balance-sheet support, but it is a valuation model input rather than an audited liquidation outcome. The base case effectively values the operating business near that support level. The bull case is only modestly above the current market value, meaning the market already gives considerable credit for a recovery. The market is wrong only if one believes the FY2026 margin collapse is largely reversible and FY2025 owner earnings can be restored with an 8% required yield; current evidence does not make that conclusion robust.

7. Key Facts, Estimates, and Judgments